Today: 20 March 2026
Exxon stock slips after Trump hints at Venezuela block — what to watch before Tuesday
13 January 2026
2 mins read

Exxon stock slips after Trump hints at Venezuela block — what to watch before Tuesday

New York, Jan 12, 2026, 18:53 EST — After-hours

  • Trump indicated he might block Exxon from pursuing investments in Venezuela after the CEO labeled the country “uninvestable”
  • Oil hit seven-week highs on concerns over Iran exports, while expectations of Venezuelan supply kept gains in check
  • Attention shifts to U.S. policy on Venezuela and Exxon’s quarterly earnings due January 30

Exxon Mobil shares slipped in after-hours trading Monday following President Donald Trump’s comment that he might block the oil giant from Venezuela’s reopening—a rare public rebuke aimed at the company’s CEO.

This episode is crucial as Washington moves fast to redirect Venezuela’s oil shipments following last week’s power shift in Caracas. Investors are scrambling to figure out which producers could tap into those barrels—and on what terms.

Exxon investors now face an extra political risk on top of an already volatile oil market. Moves benefiting Venezuela’s competitors might not shift the needle much right away, but over time, large projects there could impact cash flow.

Trump told reporters he “didn’t like” Exxon’s position after CEO Darren Woods called the country “uninvestable” given current legal and commercial conditions. Woods pointed to past asset seizures and said Exxon would require strong investment protections and changes to hydrocarbon laws before thinking about a comeback, Reuters reported. Reuters

Behind the scenes, oil executives have pushed hard for clear answers on sanctions relief, security, and contract details, stressing that reviving Venezuela’s oil sector won’t happen overnight. Carlos Bellorin, an analyst at consultancy Welligence, noted that oilfield service firms might hold back on deploying equipment while still owed large payments. Chevron’s vice chairman told Trump the company could boost output by 50% within two years through upgrades to existing infrastructure, according to Reuters. Reuters

Crude prices held steady, with Brent closing up 0.8% at $63.87 a barrel and U.S. West Texas Intermediate gaining 0.6% to $59.50—both hitting seven-week highs. Concerns over a drop in Iran’s exports amid unrest fueled the rise, though hopes for Venezuela’s export restart capped the upside. Goldman Sachs, however, warned that prices may ease later this year as fresh supply pushes the market into surplus. Reuters

Exxon shares slipped roughly 0.5% to $124.03, trading between $122.58 and $124.55 during Monday’s session, market data shows.

Energy stocks showed a mixed picture. Chevron edged up modestly, but ConocoPhillips slipped, highlighting how news from Venezuela is driving selective plays within the sector instead of pushing all names higher together. MarketWatch

The Venezuela factor remains tricky to pin down. Trump’s remarks might be more strategic posturing than policy change. But if exports from Venezuela pick up quickly, that could push crude prices lower, squeezing producers’ upstream operations — the side of the business that deals with oil and gas production.

Investors face a more immediate trigger: Exxon plans to release its fourth-quarter results on Jan. 30, followed by an earnings call at 8:30 a.m. CST, according to the company’s investor website. Exxon Mobil Corporation

Traders will be on alert before Tuesday’s open for new White House details on which companies can operate in Venezuela and under what legal terms. They’ll also track crude oil moves linked to supply news from Iran and Venezuela.

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Johnson & Johnson stock rises after Delaware court pares Auris damages as earnings near
Previous Story

Johnson & Johnson stock rises after Delaware court pares Auris damages as earnings near

GE Vernova stock pops after $1,087 price-target hike — and Wall Street’s already eyeing Jan. 28
Next Story

GE Vernova stock pops after $1,087 price-target hike — and Wall Street’s already eyeing Jan. 28

Go toTop